Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Malaria Journal
Published in: Malaria Journal 1/2010

Open Access 01-12-2010 | Research

Up- and down-modulation of liver cytochrome P450 activities and associated events in two murine malaria models

Authors: Ana Cecilia AX De-Oliveira, Renato S Carvalho, Flavio HM Paixão, Hellen S Tavares, Luciana S Gueiros, Carolina M Siqueira, Francisco JR Paumgartten

Published in: Malaria Journal | Issue 1/2010

Login to get access

Abstract

Background

The mechanisms by which malaria up and down-regulates CYP activities are not understood yet. It is also unclear whether CYP activities are modulated during non-lethal malaria infections. This study was undertaken to evaluate the time course of CYP alterations in lethal (Plasmodium berghei ANKA) and non-lethal (Plasmodium chabaudi chabaudi) murine malaria. Additionally, hypotheses on the association of CYP depression with enhanced nitric oxide (NO) production, and of CYP2a5 induction with endoplasmic reticulum dysfunction, enhanced haem metabolism and oxidative stress were examined as well.

Methods

Female DBA-2 and C57BL/6 mice were infected with P.berghei ANKA or P. chabaudi and killed at different post-infection days. Infection was monitored by parasitaemia rates and clinical signs. NO levels were measured in the serum. Activities of CYP1a (ethoxyresorufin-O-deethylase), 2b (benzyloxyresorufin-O-debenzylase), 2a5 (coumarin-7-hydroxylase) and uridine-diphosphoglucuronyl-transferase (UGT) were determined in liver microsomes. Glutathione-S-transferase (GST) activity and concentrations of gluthatione (GSH) and thiobarbituric acid-reactive substances (TBARS) were determined in the liver. Levels of glucose-regulated protein 78 (GRP78) were evaluated by immunoblotting, while mRNAs of haemoxygenase-1 (HO-1) and inducible nitric oxide synthase (iNOS) were determined by quantitative RT-PCR.

Results

Plasmodium berghei depressed CYP1a and 2b and induced 2a5 in DBA-2 mice. In P.berghei-infected C57BL/6 mice CYP activities remained unaltered. In both strains, GST and UGT were not affected by P.berghei. Plasmodium c. chabaudi depressed CYP1a and 2b and induced 2a5 activities on the day of peak parasitaemia or near this day. CYP2a5 induction was associated with over-expression of HO-1 and enhanced oxidative stress, but it was not associated with GRP78 induction, a marker of endoplasmic reticulum stress. Plasmodium chabaudi increased serum NO on days near the parasitaemia peak in both strains. Although not elevating serum NO, P.berghei enhanced iNOS mRNA expression in the liver.

Conclusion

Down-regulation of CYP1a and 2b and induction of 2a5 occurred in lethal and non-lethal infections when parasitaemia rates were high. A contribution of NO for depression of CYP2b cannot be ruled out. Results were consistent with the view that CYP2a5 and HO-1 are concurrently up-regulated and suggested that CYP2a5 induction may occur in the absence of enhanced endoplasmic reticulum stress.
Appendix
Available only for authorised users
Literature
1.
Morgan ET: Regulation of cytochrome P450 by inflammatory mediators: why and how?. Drug Metab Dispos. 2001, 29: 207-212.PubMed
2.
Aitken AE, Richardson TA, Morgan ET: Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol. 2006, 46: 123-149. 10.1146/annurev.pharmtox.46.120604.141059.CrossRefPubMed
3.
Alvares AP, Ueng TH, Scheibel LW, Hollingdale MR: Impairment of hepatic cytochrome P-450 dependent monooxygenases by the malaria parasite Plasmodium berghei. Mol Biochem Parasitol. 1984, 13: 277-282. 10.1016/0166-6851(84)90119-1.CrossRefPubMed
4.
Uhl K, Grace JM, Kocisko DA, Jennings BT, Michell AL, Brewer TG: Effects of Plasmodium berghei infection on cytochromes P-450 2E1 and 3A2. Eur J Drug Metab Pharmacokinet. 1999, 24: 169-176.CrossRefPubMed
5.
Poça KS, De-Oliveira AC, Santos MJ, Paumgartten FJ: Malaria infection modulates effects of genotoxic chemicals in the mouse bone-marrow micronucleus test. Mutat Res. 2008, 649: 28-33.CrossRefPubMed
6.
Carvalho RS, Friedrich K, De-Oliveira AC, Suarez-Kurtz G, Paumgartten FJ: Malaria downmodulates mRNA expression and catalytic activities of CYP1A2, 2E1 and 3A11 in mouse liver. Eur J Pharmacol. 2009, 616: 265-269. 10.1016/j.ejphar.2009.05.030.CrossRefPubMed
7.
De-Oliveira ACAX, Da-Matta AC, Paumgartten FJR: Plasmodium berghei (ANKA): Infection induces CYP2A5 and 2E1 while depressing other CYP isoforms in the mouse liver. Exp Parasitol. 2006, 113: 256-261. 10.1016/j.exppara.2006.01.013.CrossRefPubMed
8.
Gilmore WJ, Hartmann G, Piquette-Miller M, Marriott J, Kirby GM: Effects of lipopolysaccharide-stimulated inflammation and pyrazole-mediated hepatocellular injury on mouse hepatic Cyp2a5 expression. Toxicology. 2003, 184: 211-216. 10.1016/S0300-483X(02)00581-4.CrossRefPubMed
9.
Gilmore WJ, Kirby GM: Endoplasmic reticulum stress due to altered cellular redox status positively regulates murine hepatic CYP2A5 expression. J Pharmacol Exp Ther. 2004, 308: 600-608. 10.1124/jpet.103.060111.CrossRefPubMed
10.
Abu-Bakar A, Moore MR, Lang MA: Evidence for induced microsomal bilirubin degradation by cytochrome P450 2A5. Biochem Pharmacol. 2005, 70: 1527-1535. 10.1016/j.bcp.2005.08.009.CrossRefPubMed
11.
Francis SE, Sullivan DJ, Goldberg DE: Hemoglobin metabolism in the malaria parasite Plasmodium falciparum. Annu Rev Microbiol. 1997, 51: 97-123. 10.1146/annurev.micro.51.1.97.CrossRefPubMed
12.
Omodeo-Salè F, Motti A, Dondorp A, White NJ, Taramelli D: Destabilization and subsequent lysis of human erythrocytes induced by Plasmodium falciparum haem products. Eur J Haematol. 2005, 74: 324-332. 10.1111/j.1600-0609.2004.00352.x.CrossRefPubMed
13.
Brinkmann V, Kaufmann SHE, Simon MM, Fischer H: Role of macrophages in malaria: O2 metabolite production and phagocytosis by splenic macrophages during lethal Plasmodium berghei and self-limiting Plasmodium yoelii infection in mice. Infect Immun. 1984, 44: 743-746.PubMedCentralPubMed
14.
Maines MD, Trakshel GM, Kutty RK: Characterization of two constitutive forms of rat liver microsomal heme oxygenase. Only one molecular species of the enzyme is inducible. J Biol Chem. 1986, 261: 411-419.PubMed
15.
Tenhunen R, Marver HS, Schmid R: The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci USA. 1968, 61: 748-755. 10.1073/pnas.61.2.748.PubMedCentralCrossRefPubMed
16.
Khatsenko OG, Gross SS, Rifkind AB, Vane JR: Nitric oxide is a mediator of the decrease in cytochrome P450-dependent metabolism caused by immunostimulants. Proc Natl Acad Sci USA. 1993, 90: 11147-11151. 10.1073/pnas.90.23.11147.PubMedCentralCrossRefPubMed
17.
Khatsenko O, Kikkawa Y: Nitric Oxide Differentially Affects Constitutive Cytochrome P450 Isoforms in Rat Liver. J Pharmacol Exp Ther. 1997, 250: 1463-1470.
18.
Sewer MB, Barclay TB, Morgan ET: Down-regulation of cytochrome P450 mRNAs and proteins in mice lacking a functional NOS2 gene. Mol Pharmacol. 1998, 54: 273-279.PubMed
19.
Li YQ, Prentice DA, Howard ML, Mashford ML, Desmond PL: Bilirubin and bile acids may modulate their own metabolism via regulating uridine diphosphate-glucuronosyltransferase expression in the rat. J Gastroenterol Hepatol. 2000, 15: 865-867. 10.1046/j.1440-1746.2000.02223.x.CrossRefPubMed
20.
De-Oliveira ACAX, Ribeiro-Pinto LF, Paumgartten FJR: In vitro inhibition of CYP2B1 monooxygenase by myrcene and other monoterpenoid compounds. Toxicol Lett. 1997, 92: 39-46. 10.1016/S0378-4274(97)00034-9.CrossRefPubMed
21.
Fowler BA, Kleinow KM, Squibb KS, Lucier GW, Hayes AW: Organelles as Tools in Toxicology. Principles and Methods of Toxicology. Edited by: Wallace Hayes A. 1994, Chapter 33: 222-223. 3
22.
Abel EL, Bammler TK, Eaton DL: Biotransformation of methyl parathion by glutathione S-transferase. Toxicol Sci. 2004, 79: 224-232. 10.1093/toxsci/kfh118.CrossRefPubMed
23.
Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem. 1976, 72: 248-254. 10.1016/0003-2697(76)90527-3.CrossRefPubMed
24.
Kennedy SW, Jones SP: Simultaneous measurement of cytochrome P450 catalytic activity and total protein concentration with fluorescent plate reader. Anal Biochem. 1994, 222: 217-223. 10.1006/abio.1994.1476.CrossRefPubMed
25.
van Iersel M, Walters DG, Price RJ, Lovell DP, Lake BG: Sex and strain differences in mouse hepatic microsomal coumarin-7-hydroxylase activity. Food Chem Toxicol. 1994, 32: 387-390. 10.1016/0278-6915(94)90078-7.CrossRefPubMed
26.
Bock KW, Burchell B, Dutton GJ, Hanninen O, Mulder GJ, Owens IS, Siest G, Tephly TR: UDP-glucuronosyltransferase activities Guidelines for consistent interim terminology and assay conditions. Biochem Pharmacol. 1983, 32: 953-955. 10.1016/0006-2952(83)90610-X.CrossRefPubMed
27.
Martin ST, Black SD: Detergent effects in rabbit liver microsomal UDP-glucuronosyltransferase studied by means of a continuous spectrophotometric assay with p-nitrophenol. Biochem Biophys Res Commun. 1994, 200: 1093-1098. 10.1006/bbrc.1994.1562.CrossRefPubMed
28.
Habig WH, Pabst MJ, Jakoby WB: Glutathione S-transferases The first enzymatic step in mercapturic acid formation. J Biol Chem. 1974, 249: 7130-7139.PubMed
29.
Cao Z, Li Y: The chemical inducibility of mouse cardiac antioxidants and phase 2 enzymes in vivo. Biochem Biophys Res Commun. 2004, 17: 1080-1088. 10.1016/j.bbrc.2004.03.156.CrossRef
30.
Zhu H, Li Y, Trush MA: Characterization of benzo[a]pyrene quinone-induced toxicity to primary cultured bone marrow stromal cells from DBA-2 mice: potential role of mitochondrial dysfunction. Toxicol Appl Pharmacol. 1995, 130: 108-120. 10.1006/taap.1995.1015.CrossRefPubMed
31.
Cao Z, Hardej D, Trombetta LD, Trush MA, Li Y: Induction of cellular glutathione and glutathione S-transferase by 3H-1,2-dithiole-3-thione in rat aortic smooth muscle A10 cells: protection against acrolein-induced toxicity. Atherosclerosis. 2003, 166: 291-302. 10.1016/S0021-9150(02)00331-3.CrossRefPubMed
32.
Hermes-Lima M, Wang EM, Schulman HM, Storey KB, Ponka O: Deoxyribose degradation catalyzed by Fe(III)-EDTA. Kinetic aspects and potential uselfulness for sub-micromolar iron measurements. Mol Cell Biochem. 1994, 137: 65-73. 10.1007/BF00926041.CrossRefPubMed
33.
Schmidt HH, Wilke P, Evers B, Böhme E: Enzymatic formation of nitrogen oxides from L-arginine in bovine brain cytosol. Biochem Biophys Res Commun. 1989, 165: 284-291. 10.1016/0006-291X(89)91067-X.CrossRefPubMed
34.
Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970, 227: 680-685. 10.1038/227680a0.CrossRefPubMed
35.
de Souza JB, Riley EM: Cerebral malaria: the contribution of studies in animal models to our understanding of immunopathogenesis. Microbes Infect. 2002, 4: 291-300. 10.1016/S1286-4579(02)01541-1.CrossRefPubMed
36.
Ferreira A, Balla J, Jeney V, Balla G, Soares MP: A central role for free heme in the pathogenesis of severe malaria: the missing link. J Mol Med. 2008, 86: 1097-1111. 10.1007/s00109-008-0368-5.CrossRefPubMed
37.
Seixas E, Gozzelino R, Chora A, Ferreira A, Silva G, Larsen R, Rebelo S, Penido C, Smith NR, Coutinho A, Soares MP: Heme oxygenase-1 affords protection against noncerebral forms of severe malaria. Proc Natl Acad Sci USA. 2009, 106: 15837-15842. 10.1073/pnas.0903419106.PubMedCentralCrossRefPubMed
38.
Hosoi T, Saito A, Kume A, Okuma Y, Nomura Y, Ozawa K: Vanadate inhibits endoplasmic reticulum stress responses. Eur J Pharmacol. 2008, 594: 44-48. 10.1016/j.ejphar.2008.07.034.CrossRefPubMed
39.
Kirby GM, Pelkonen P, Vatanasapt V, Camus A-M, Wild CP, Lang MA: Association of liver fluke (Opistorchis viverrini) infestation with increased expression of cytochrome P450 and carcinogen metabolism in male hamster liver. Mol Carcinog. 1994, 11: 81-89. 10.1002/mc.2940110205.CrossRefPubMed
40.
Montero R, Serrano L, D'avila VM, Ito A, Plancarte A: Infection of rats with Taenia taeniformis metacestodes increases hepatic CYP450, induces the activity of CYP1A1, CYP2B1 and COH isoforms and increases the genotoxicity of the procarcinogens benzo[a]pyrene, cyclophosphamide and aflatoxin B(1). Mutagenesis. 2003, 18: 211-216. 10.1093/mutage/18.2.211.CrossRefPubMed
41.
Richardson TA, Sherman M, Antonovic L, Kardar SS, Strobel HW, Kalman D, Morgan ET: Hepatic and renal cytochrome p450 gene regulation during citrobacter rodentium infection in wild-type and toll-like receptor 4 mutant mice. Drug Metab Dispos. 2006, 34: 354-356.PubMedCentralPubMed
42.
Nichols KD, Kirby GM: Expression of cytochrome P4502A5 in a glucose-6-phosphate dehydrogenase-deficient mouse model of oxidative stress. Biochem Pharmacol. 2008, 75: 1230-1239. 10.1016/j.bcp.2007.10.032.CrossRefPubMed
43.
Salonpaa P, Krause K, Pelkonen O, Raunio H: Up-regulation of CYP2A5 expression by porphyrinogenic agents in mouse liver. Naunyn Schmiedebergs Arch Pharmacol. 1995, 351: 446-452. 10.1007/BF00169087.CrossRefPubMed
44.
Murdoch RT, Ghabrial H, Smallwood RA, Morgan DJ: Effects of malaria on phenol conjugation pathways in perfused rat liver. Biochem Pharmacol. 1992, 43: 1229-1234. 10.1016/0006-2952(92)90496-6.CrossRefPubMed
45.
Ismail S, Kokwaro GO, Back DJ, Edwards G: Effect of malaria infection on the pharmacokinetics of paracetamol in rat. Xenobiotica. 1994, 24: 527-533. 10.3109/00498259409043255.CrossRefPubMed
46.
Ahmad R, Srivastava AK: Effect of Plasmodium yoelii nigeriensis infection on hepatic and splenic glutathione-S-transferase(s) in Swiss albino and db/+ mice: efficacy of mefloquine and menadione in antimalarial chemotherapy. Parasitology. 2007, 134: 931-938. 10.1017/S003118200700234X.CrossRefPubMed
47.
Brunet LR: Nitric oxide in parasitic infections. Int Immunopharmacol. 2001, 1: 1457-1467. 10.1016/S1567-5769(01)00090-X.CrossRefPubMed
48.
Nahrevanian H: Immune effector mechanisms of the nitric oxide pathway in malaria: cytotoxicity versus cytoprotection. Braz J Infect Dis. 2006, 10: 283-292. 10.1590/S1413-86702006000400014.CrossRefPubMed
49.
Sobolewski P, Gramaglia I, Frangos JA, Intaglietta M, Heyde van der H: Plasmodium berghei resists killing by reactive oxygen species. Infect Immun. 2005, 3: 6704-6710. 10.1128/IAI.73.10.6704-6710.2005.CrossRef
50.
Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO, Schechter AN, Gladwin MT: Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002, 8: 1383-1389. 10.1038/nm799.CrossRefPubMed
51.
Lee CM, Kim BY, Li L, Morgan ET: Nitric oxide-dependent proteasomal degradation of cytochrome P450 2B proteins. J Biol Chem. 2008, 283: 889-898. 10.1074/jbc.M708821200.PubMedCentralCrossRefPubMed
52.
Gu X, Ke S, Liu D, Sheng T, Thomas PE, Rabson AB, Gallo MA, Xie W, Tian Y: Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents. J Biol Chem. 2006, 281: 17882-17889. 10.1074/jbc.M601302200.CrossRefPubMed
53.
Franklin BS, Parroche P, Ataíde MA, Lauw F, Ropert C, de Oliveira RB, Pereira D, Tada MS, Nogueira P, da Silva LH, Bjorkbacka H, Golenbock DT, Gazzinelli RT: Malaria primes the innate immune response due to interferon-gamma induced enhancement of toll-like receptor expression and function. Proc Natl Acad Sci USA. 2009, 106: 5789-5794. 10.1073/pnas.0809742106.PubMedCentralCrossRefPubMed
54.
Trenholme GM, Williams RL, Rieckman KH, Frischer H, Carson PE: Quinine disposition during malaria and during induced fever. Clin Pharmacol Ther. 1976, 19: 459-467.PubMed
55.
Akinyinka OO, Sowunmi A, Honeywell R, Renwick AG: The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians. Eur J Clin Pharmacol. 2000, 56: 159-165. 10.1007/s002280050735.CrossRefPubMed
Metadata
Title
Up- and down-modulation of liver cytochrome P450 activities and associated events in two murine malaria models
Authors
Ana Cecilia AX De-Oliveira
Renato S Carvalho
Flavio HM Paixão
Hellen S Tavares
Luciana S Gueiros
Carolina M Siqueira
Francisco JR Paumgartten
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2010
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/1475-2875-9-81

Other articles of this Issue 1/2010

Malaria Journal 1/2010 Go to the issue

Research

Monitoring of malaria parasite resistance to chloroquine and sulphadoxine-pyrimethamine in the Solomon Islands by DNA microarray technology

Methodology

Simultaneous identification of the Anopheles funestus group and Anopheles longipalpis type C by PCR-RFLP

Research

Comparison of Plasmodium berghei challenge models for the evaluation of pre-erythrocytic malaria vaccines and their effect on perceived vaccine efficacy

Research

Wash durability and optimal drying regimen of four brands of long-lasting insecticide-treated nets after repeated washing under tropical conditions

Research

Anopheles larval abundance and diversity in three rice agro-village complexes Mwea irrigation scheme, central Kenya

Research

Relationships between anopheline mosquitoes and topography in West Timor and Java, Indonesia
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits